Literature DB >> 7669261

Absorption interactions with fluoroquinolones. 1995 update.

B M Lomaestro1, G R Bailie.   

Abstract

The utility of the fluoroquinolone class of antibiotics is rapidly expanding due to their favourable pharmacokinetic profile and the continuing development of new compounds. These agents are often used for indications not successfully treated with other orally available antimicrobials in the past, or for 'step-down' therapy in patients originally treated with intravenous agents. As the usage of these agents expands for serious systemic infections, knowledge of absorptive interactions with fluoroquinolones becomes paramount. Fluoroquinolones are often utilised in dosages and against modestly susceptible pathogens which allow a narrow margin for acceptable decreases in bioavailability. Chelation interactions with multivalent cations can result in inactivation of the fluoroquinolone with ramifications in vitro and in vivo. Chelation interactions have been reported to occur in between 22 and 76% of patients prescribed fluoroquinolones. Concurrent administration of magnesium-aluminum antacids and sucralfate has the greatest effect on the bioavailability of quinolones followed by iron, calcium and zinc. Spacing doses of fluoroquinolones and interactants has been suggested as a method of ensuring adequate quinolone absorption, but this can make optimal administration of the cation interactant difficult, if not impossible.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669261     DOI: 10.2165/00002018-199512050-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  128 in total

1.  Interference of dairy products with the absorption of ciprofloxacin.

Authors:  P J Neuvonen; K T Kivistö; P Lehto
Journal:  Clin Pharmacol Ther       Date:  1991-11       Impact factor: 6.875

2.  Clinical and chemical interactions between iron preparations and ciprofloxacin.

Authors:  M Kara; B B Hasinoff; D W McKay; N R Campbell
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

3.  Ciprofloxacin and antacids.

Authors:  L C Preheim; T A Cuevas; J S Roccaforte; M A Mellencamp; M J Bittner
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

4.  Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans.

Authors:  U Jaehde; F Sörgel; U Stephan; W Schunack
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 5.  Usual and unusual antibacterial effects of quinolones.

Authors:  Y X Furet; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

6.  A comparison of sucralfate dosage schedule in duodenal ulcer healing. Two grams twice a day versus one gram four times a day.

Authors:  I N Marks; J P Wright; N H Gilinsky; A H Girdwood; R Tobias; E Boyd; I Kalvaria; S J O'Keefe; K Newton; W Lucke
Journal:  J Clin Gastroenterol       Date:  1986-08       Impact factor: 3.062

7.  Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics.

Authors:  J A Paladino; H E Sperry; J M Backes; J A Gelber; D J Serrianne; T J Cumbo; J J Schentag
Journal:  Am J Med       Date:  1991-11       Impact factor: 4.965

8.  Pharmacokinetic considerations in quinolone therapy.

Authors:  C H Nightingale
Journal:  Pharmacotherapy       Date:  1993 Mar-Apr       Impact factor: 4.705

9.  Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state.

Authors:  T Kalager; A Digranes; T Bergan; T Rolstad
Journal:  J Antimicrob Chemother       Date:  1986-06       Impact factor: 5.790

10.  Interaction of divalent cations, quinolones and bacteria.

Authors:  A J Marshall; L J Piddock
Journal:  J Antimicrob Chemother       Date:  1994-10       Impact factor: 5.790

View more
  26 in total

Review 1.  Quinolones: which generation for which microbe?

Authors:  M K Lee; M S Kanatani
Journal:  West J Med       Date:  1999-06

Review 2.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

3.  Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.

Authors:  H Stass; D Kubitza
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.

Authors:  H Stass; D Kubitza
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.

Authors:  H Stass; U Schühly; J G Möller; H Delesen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Pharmacokinetic and pharmacodynamic studies of drug interaction following oral administration of imipramine and sodium alginate in rats.

Authors:  Shinichi Watanabe; Katsuya Suemaru; Naoto Inoue; Kimie Imai; Tachio Aimoto; Hiroaki Araki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-01       Impact factor: 3.000

Review 7.  The effect of zinc supplementation on blood pressure: a systematic review and dose-response meta-analysis of randomized-controlled trials.

Authors:  Seyed Mohammad Mousavi; Manije Darooghegi Mofrad; Israel Júnior Borges do Nascimento; Alireza Milajerdi; Tahereh Mokhtari; Ahmad Esmaillzadeh
Journal:  Eur J Nutr       Date:  2020-02-24       Impact factor: 5.614

Review 8.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 9.  Drug interactions with antiviral drugs.

Authors:  A M Taburet; E Singlas
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

10.  Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.

Authors:  Reza Khosravan; Brian Grabowski; Jing-Tao Wu; Nancy Joseph-Ridge; Laurent Vernillet
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.